Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.56 |
| ▸ | APP | P05067 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968808 | 0.87 | ESR1 (0.60) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL15968728 | 0.78 | ESR1 (0.60) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL15968370 | 0.77 | ACACA (0.58) | ACACA | |
| SCHEMBL15968178 | 0.77 | ACACA (0.50) | FFAR4ACACA | |
| SCHEMBL1378406 | 0.72 | ESR2 (1.00) | ESR1ESR2NPC1RAB9A | |
| SCHEMBL15968715 | 0.72 | ACACA (0.54) | ACACA | |
| SCHEMBL15968188 | 0.71 | ESR1 (0.40) | ESR1ESR2FFAR4 | |
| SCHEMBL27090228 | 0.71 | ESR1 (0.96) | ESR1ESR2APPNPC1RAB9A | |
| SCHEMBL15968829 | 0.71 | ACACB (0.42) | FFAR4ACACA | |
| SCHEMBL15968702 | 0.71 | ACACB (0.49) | ACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ESR1 2402/4885ESR2 2876/4885APP 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.